Most cited papers from Velindre Cancer Centre

Velindre Cancer Centre

What are the most cited papers from Velindre Cancer Centre?

The most cited paper from Velindre Cancer Centre is "Abiraterone and Increased Survival in Metastatic Prostate Cancer" (Johann Sebastian De Bono et al., 2011), with 4,448 citations. Next come "EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent" (3,282) and "EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent" (2,876).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 341 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Abiraterone and Increased Survival in Metastatic Prostate Cancer Johann Sebastian De Bono et al. · New England Journal of Medicine Open access	25 May 2011	4,448
2	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent Nicolas Mottet et al. · European Urology Open access	31 Aug 2016	3,282
3	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent Nicolas Mottet et al. · European Urology Open access	7 Nov 2020	2,876
4	PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer Antonino Glaviano et al. · Molecular Cancer Open access	18 Aug 2023	2,108
5	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Nicholas David James et al. · The Lancet Open access	21 Dec 2015	1,985
6	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution Christopher Abbosh et al. · Nature Open access104 authors	25 Apr 2017	1,978
7	Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial John P. Neoptolemos et al. · The Lancet Open access	24 Jan 2017	1,953
8	EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013 Axel Heidenreich, Patrick J. Bastian, Joaquim Bellmunt et al. · European Urology	6 Oct 2013	1,951
9	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy Nicholas David James et al. · New England Journal of Medicine Open access	3 Jun 2017	1,806
10	The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials Joanne Haviland, John R. Owen, John A. Dewar et al. · The Lancet Oncology Open access	18 Sep 2013	1,479
11	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer Philip A Cornford, Joaquim Bellmunt, M. Bolla et al. · European Urology	9 Sep 2016	1,461
12	Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Karim S. Fizazi, Howard I. Scher, Arturo Molina et al. · The Lancet Oncology	17 Sep 2012	1,402
13	Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation Hina Kalra et al. · PLoS Biology Open access	18 Dec 2012	1,391
14	Guidelines for the management of thyroid cancer Petros Perros, Kristien Boelaert, Steve Colley et al. · Clinical Endocrinology	Jul 2014	1,378
15	EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer Axel Heidenreich, Patrick J. Bastian, Joaquim Bellmunt et al. · European Urology	12 Nov 2013	1,361
16	Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial David Paul Dearnaley et al. · The Lancet Oncology Open access	22 Jun 2016	1,350
17	Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial Christopher Parker et al. · The Lancet Open access	21 Oct 2018	1,289
18	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer Philip A Cornford et al. · European Urology Open access	8 Oct 2020	1,142
19	Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial Andrew N.J. Tutt et al. · Nature Medicine Open access	27 Apr 2018	920
20	How pure are your vesicles? Jason Paul Webber, Aled Clayton · Journal of Extracellular Vesicles Open access	2013	831
21	Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis Andrew G. Renehan, Lee Malcomson, Richard A Emsley et al. · The Lancet Oncology	18 Dec 2015	813
22	Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial François‐Clément Bidard et al. · Journal of Clinical Oncology Open access	18 May 2022	754
23	Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial R.D. James, Rob Glynne‐Jones, Helen Margaret Meadows et al. · The Lancet Oncology Open access	9 Apr 2013	738
24	Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial Tom Waddell, Ian Chau, David Cunningham et al. · The Lancet Oncology Open access	17 Apr 2013	733
25	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial Joaquı́n Mateo et al. · The Lancet Oncology Open access	2 Dec 2019	650
26	Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis Dragan Ilić, Mia Djulbegovic, Jae Hung Jung et al. · BMJ ReviewOpen access	5 Sep 2018	649
27	Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression Aled Clayton, John Paul Mitchell, Jacquelyn Court et al. · The Journal of Immunology Open access	Jun 2008	585
28	Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Padraig Richard Warde, Malcolm Mason, Keyue Ding et al. · The Lancet Open access	3 Nov 2011	584
29	Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial Michel Seymour, Tim Maughan, Jonathan A. Ledermann et al. · The Lancet	Jul 2007	569
30	Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry Aled Clayton, Jacquelyn Court, Hossein Navabi et al. · Journal of Immunological Methods	2001	557
31	Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production Aled Clayton, Saly Al‐Taei, Jason Paul Webber et al. · The Journal of Immunology Open access	16 Jun 2011	548
32	The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review Nicola Fossati et al. · European Urology ReviewOpen access	24 Jan 2017	545
33	Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review Thomas Van den Broeck et al. · European Urology ReviewOpen access	17 Oct 2018	534
34	Human Tumor-Derived Exosomes Selectively Impair Lymphocyte Responses to Interleukin-2 Aled Clayton, John Paul Mitchell, Jacquelyn Court et al. · Cancer Research Open access	Aug 2007	518
35	Classification of current anticancer immunotherapies Lorenzo Galluzzi et al. · Oncotarget Open access	18 Dec 2014	475
36	Induction of heat shock proteins in B-cell exosomes Aled Clayton, Attilla Turkes, Hossein Navabi et al. · Journal of Cell Science Open access	26 Jul 2005	454
37	Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial R.T.D. Oliver, MD Mason, GM Mead et al. · The Lancet Open access	Jul 2005	449
38	Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019) Nicholas David James, Melissa Ruth Spears, Noel William Clarke et al. · European Urology Open access	7 Oct 2014	440
39	Breast-Cancer Adjuvant Therapy with Zoledronic Acid Robert E. Coleman, Helen Marshall, David Cameron et al. · New England Journal of Medicine Open access	25 Sep 2011	422
40	Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial Michel Seymour, Lindsay C Thompson, Harpreet Singh Wasan et al. · The Lancet Open access	May 2011	421
41	Breast-cancer Adjuvant Therapy With Zoledronic Acid Robert Edward Coleman, Helen C. Marshall, David Cameron et al. · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)	13 Oct 2011	414
42	Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines Vincent Grégoire et al. · Radiotherapy and Oncology Open access	24 Nov 2017	414
43	Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial Noel William Clarke, Paweł Wiechno, B. Yа. Alekseev et al. · The Lancet Oncology Open access	4 Jun 2018	412
44	Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data Claire Louise Vale, Sarah Burdett, Larysa H. M. Rydzewska et al. · The Lancet Oncology ReviewOpen access	21 Dec 2015	408
45	Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial N.W. Clarke et al. · Annals of Oncology Open access	9 Sep 2019	404
46	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial Cora Nanette Sternberg et al. · The Lancet Oncology	11 Dec 2014	390
47	Proteomics Analysis of Bladder Cancer Exosomes Joanne Louise Welton, Sanjay Khanna, Peter J. Giles et al. · Molecular & Cellular Proteomics Open access	11 Mar 2010	388
48	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol Gerhardt Attard et al. · The Lancet ReviewOpen access173 authors	23 Dec 2021	387
49	Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial T. Crosby, Chris N Hurt, Stephen J. Falk et al. · The Lancet Oncology Open access	25 Apr 2013	387
50	Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer Anne O’Donnell, Ian Robert Judson, Mitch Dowsett et al. · British Journal of Cancer Open access	18 May 2004	385

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.